Clinical Trials
7 trialsNCT03768063 2026-04-28
IMbrella B
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT03498521 2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2 Completed
NCT01739764 2021-01-07
An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol
Hoffmann-La Roche
Phase 4 Completed
NCT01767623 2018-02-13
A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Participants
Hoffmann-La Roche
Phase 1 Completed
NCT01974258 2016-11-02
Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients
Hoffmann-La Roche
Phase 1 Withdrawn
NCT01286753 2016-09-07
A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation
Hoffmann-La Roche
Phase 2 Completed
NCT01673737 2015-04-10
A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer
Sanofi
Phase 1 Completed